Occam Places Chief Development Officer of Groundbreaking Longevity Player, Loyal
In May 2024, Occam recruited Hubert Chen, MD as Chief Development Officer of Loyal, a biotech company pioneering longevity drugs for dogs. Since its founding in 2019, Loyal has raised $125M from blue chip VCs including Bain and Khosla. The company currently has three drugs in development to extend healthy lifespan in dogs and anticipates the most advanced drug will be available in early 2025, pending FDA conditional approval.
Chen brings two decades of translational and clinical development experience within human therapeutics to Loyal’s animal health pipeline. Hubert came to Loyal from Forte Biosciences, where he served as Chief Medical Officer. He was formerly the Chief Medical Officer of metabolic biotech Metacrine and the Chief Scientific and Medical Officer of protein technology platform biotech Pfenex, leading up to its sale to Ligand Pharmaceuticals. Hubert has an MD from Columbia University and a BA from Stanford University.
View recent Placements
.jpg)
.jpg)
.jpg)
.jpg)
DISCOVER OCCAM GLOBAL
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies.
Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.